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ABSTRACT
The formation of the Tat-protein/TAR-RNA complex
is a crucial step in the regulation of human immu-
nodeficiency virus (HIV)-gene expression. To obtain
full-length viral transcripts the Tat/TAR complex has
to recruit the positive transcription elongation factor
complex (P-EFTb), which interacts with TAR through
its cyclin T1 (CycT1) component. Mutational studies
identified the TAR hexanucleotide loop as a crucial
region for contacting CycT1. Interfering with the
interaction between the Tat/CycT1 complex and the
TAR-RNA is an attractive strategy for the design of
anti-HIV drugs. Positively charged molecules, like
aminoglycosides or peptidomimetics, bind the TAR-
RNA, disrupting the Tat/TAR complex. Here, we
investigate the complex between the HIV-2 TAR-RNA
and a neooligoaminodeoxysaccharide by NMR spec-
troscopy. In contrast to other aminoglycosides, this
novel aminoglycoside analogue contacts simultan-
eously the bulge residues required for Tat binding
and the A35 residue of the hexanucleotide loop.
Upon complex formation, the loop region under-
goes profound conformational changes. The novel
binding mode, together with the easy accessibility
of derivatives for the neooligoaminodeoxysacchar-
ide, could open the way to the design of a new
class of TAR-RNA binders, which simultaneously
inhibit the formation of both the Tat/TAR binary
complex and the Tat/TAR/CycT1 ternary complex
by obstructing both the bulge and loop regions of
the RNA.
INTRODUCTION
Following the discovery that RNA plays a major role in
several cellular functions, as for example transcriptional con-
trol and catalysis, a great deal of biochemical and structural
research has been initiated around RNA, including its
identification as a potential target for anti-viral therapy. The
trans-activating region (TAR) RNA of the human immunode-
ficiency virus (HIV) is a particularly attractive example of
the RNA-based drug discovery process. The formation of
full-length viral transcripts requires the interaction of the
TAR-RNA with the transcription activator protein, Tat (1).
The Tat/TAR complex recruits the positive transcription
elongation factor complex (P-EFTb), which activates the
RNA polymerase II stalled at the TAR-RNA site and enables
viral replication (2,3). The loop region of the TAR-RNA
plays a key role in binding the CycT1 unit of the P-EFTb
complex (4). Disruption of the Tat/TAR interaction inhibits
the production of complete viral transcripts, as the P-EFTb
complex cannot bind the TAR-RNA in the absence of the
Tat-protein (2). Thus, the interaction of the TAR-RNA with
both the Tat-protein and the P-EFTb complex represents an
appealing target for anti-viral therapy.
The TAR-RNAs from HIV-1 and HIV-2 differ in the size
of the bulge, which comprises 3 nt (UCU) in the HIV-1 and
2 nt (UU) in the HIV-2 (Figure 1B). Both TAR-RNAs
recognize the Tat-protein in a similar manner. Of critical
importance is the U23 nucleotide in the TAR bulge and the
(G26–C39) and the (A27–U38) base pairs in the upper stem
(Figure 1B) (5–7).
Given the relevance of the TAR-RNA as a potential
therapeutic target, much work has been directed towards
the synthesis and screening of small organic compounds
that selectively bind to the TAR-RNA, thereby inhibiting
the formation of the Tat/TAR complex. As a result of these
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studies, a number of small molecules have been found to
interact with the TAR-RNA inhibiting viral transcription in
HeLa cells (8–10).
The cationic antibiotics of the aminoglycoside family bind
to several RNA motifs by specifically recognizing their 3D
structure (11). In particular, they have been proven to exert
an inhibitory effect on the binding of the Tat-protein to the
TAR-RNA (12–14). The structure of the TAR-RNA in com-
plex with neomycin B has been investigated by NMR (15):
neomycin B binds the TAR-RNA in the minor groove of
the lower stem, which results in an allosteric inhibition of
Tat binding to TAR caused by a reduction of the major
groove volume in the upper stem.
Aminoglycosides are valuable instruments to study the
structural basis of RNA recognition and inhibition of function
by cationic organic molecules. However, their use as RNA-
targeting drugs is impeded by several drawbacks, such as
low specificity, high toxicity and development of resistance
(16–18). These considerations underline the continuous
need for new compounds that share an aminoglycosidic scaf-
fold but can be easily derivatized to obtain drug leads with a
better pharmacological profile.
Here we present the structure of the HIV-2 TAR-RNA
bound to a cyclic neooligoaminodeoxysaccharide (Scheme 1).
The synthesis of this compound has been reported previously
(19). This class of aminoglycoside analogues is unique in the
fact that they are easily synthesized via metathesis olefination
and provide novel methods of derivatization and functional
group modification. The structural analysis conducted here
reveals attractive features in the interaction of this ligand
with the TAR-RNA. The aminoglycoside analogue 1 binds
to two sites of the TAR-RNA: (i) the bulge and loop regions
on the major groove side of the upper stem; and (ii) the minor
groove of the lower stem. In contrast to natural aminoglycos-
ides and like argininamide, 1 binds to the crucial residues of
the TAR bulge required for Tat binding. Additionally, 1
extensively contacts the A35 residue of the dynamic hexanuc-
leotide loop. Upon binding of 1 to A35, the loop becomes
more ordered. Such structural stabilization could represent a
general mechanism by which the Tat protein pre-orders the
loop of the TAR-RNA for the binding of the P-TEFb com-
plex. Thus, the simultaneous targeting of both the bulge and
the loop of the TAR-RNA by positively charged molecules
could result in a more efficient inhibition of the binding
of both the Tat-protein and the P-TEFb complex to the
TAR-RNA.
MATERIALS AND METHODS
Sample preparation
The TAR-RNA was obtained by in vitro transcription using
T7-polymerase expressed and purified in-house. 15N/13C-
labeled NTPs were purchased from Spectra Stable Isotopes.
Scheme 1. Aminoglycoside analogue 1. Sugar and linker units are numbered
clockwise from 1 to 8.
Figure 1. Chemical shift mapping of TAR-binding sites. (A) Superposition of
the base region of a C–H correlation for the HIV-2 TAR-RNA free (black)
and in complex with the aminoglycoside analogue 1 (red). The acquisition
dimensions were 128 points (13C) and 2048 points (1H); each spectrum was
acquired for a total of 5 h on a 600 MHz Bruker AVANCE spectrometer. (B)
Sequence of the TAR-RNA. The lower stem of the free TAR-RNA comprises
the base pairs from G16–C46 to A22–U40, while the upper stem comprises
the base pairs from G26–C39 to C29–G36. The most significant chemical
shifts changes upon binding of the TAR-RNA to 1 are observed either for the
base or for the ribose C and H resonances of A22, U23, G26, G32, G34 and
A35 (rendered in red). Less prominent chemical shift changes are observed
for G21, U25, G28, C29, U31, G33, G36 and G43 (rendered in light blue).
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The RNA was purified by gel electrophoresis. An aliquot of
20 ml transcription reaction yielded 5 mg of pure RNA. The
aminoglycoside analogue 1 was obtained by chemical syn-
thesis as described before (19).
NMR spectroscopy
NMR spectra were acquired using a 0.3 mM sample of
13C/15N-labeled HIV-2 TAR-RNA dissolved in either D2O
or H2O/D2O (90/10%), containing 50 mM phosphate buffer
at pH 6.4. Compound 1 was titrated in concentrations varying
from 0.3 to 30 mM. The chemical shift changes of the reson-
ances of both the base C5/C6/C8/H5/H6/H8 and the sugar
C10/H10 atoms of the RNA were monitored in HSQC spectra
(20) during the titration. Standard NMR methods were
employed to assign the TAR-RNA in the complex (see also
Supplementary Data) (3,21).
Intermolecular NOEs from the TAR-RNA to the ligand
were assigned from a 3D 13C-edited/12C-filtered HSQC-
NOESY spectrum in D2O with a mixing time of 200 ms
(22), where the NOEs between the 13C-labeled RNA and
the unlabeled aminoglycoside could be selectively observed.
The aminoglycoside being in fast exchange between the
free and bound forms, no intramolecular NOE restraints
could be derived for the aminoglycoside in the complex.
RNA intramolecular NOEs were derived from a 3D
13C-HSQC-NOESY and from a base-selective high-resolution
3D 13C-HSQC-NOESY (23) with mixing time of 100 ms.
The sugar pucker was defined as either C20-endo or
C30-endo depending on the J coupling constants between H10
and H20 derived from a 2D-HCCH-E.COSY spectrum (24).
15N-labeled aminoglycoside (25) was mixed with
unlabeled TAR-RNA to attempt the measurement of H-
bond mediated JNP couplings to confirm or exclude the pres-
ence of hydrogen bonding between the amino groups of the
aminoglycoside and the phosphate backbone of the RNA.
The J-quantitative method (26) was used to measure the
JNP couplings in an H–N 2D correlation. The
15N chemical
shift of the amino group confirmed that all four groups of 1
are protonated in the NMR buffer. The resonances of the
amino protons of 1 could not be observed due to fast
exchange with the solvent.
T1 relaxation times of the base C8/C6 carbons were meas-
ured in 13C-1H correlations using relaxation delays of 5, 10,
20, 30, 40, 60, 80, 100, 120, 160, 200, 300, 400, 600, 800 and
1200 ms.
The simultaneous presence of the negatively charged RNA
and an excess of the positively charged ligand deterred us
from using phages or bicelles to attempt the alignment of
the RNA/ligand complex. Instead, we measured field-induced
residual dipolar couplings (fiRDC) (27), which linearly scale
with the square of the field strength. We measured the 1H-13C
splitting (J + D) of the C2H2, C6H6, C8H8 and C10H10 at
600, 700 and 800 MHz. The dipolar couplings at 800 MHz
were derived by linear fitting of the three values and extra-
polation to zero magnetic field to obtain the value of J.
In the refinement procedure we employed only those
RDCs that showed a linear relationship to B20 within the
experimentally determined error limits (37 RDCs in total,
excluding the two-base bulge, the loop and the two terminal
residues).
Structure calculation
Restrained molecular dynamics (rMD) combined with energy
minimization in XPLOR-NIH (28) was employed to obtain
the final ensemble of structures of the TAR/neooligo-
aminodeoxysaccharide complex. The restraints used in the
calculations comprised a total of 447 NOEs for the RNA
(320 intranucleotide and 127 internucleotide NOEs), 55 inter-
molecular NOEs, 44 experimental dihedral angle restraints
defining the ribose pucker for 22 nt, 41 non-experimental
dihedral angle restraints defining the backbone angles a, b,
z and e in the lower stem, 72 H-bond restraints defining
10 bp for stretches 16–21, 41–46 and 26–29, 36–39 and 10 res-
traints defining the planarity of the base pairs (Supplementary
Data).
Chemical shift mapping and intermolecular NOEs identi-
fied three regions for the binding of the aminoglycoside ana-
logue 1 on the TAR-RNA: the bulge and loop regions on the
side of the upper stem major groove and the minor groove of
the lower stem (Figure 1). As the contacts between the
aminoglycoside analog 1 and the upper stem, bulge and
loop of the TAR-RNA are much more extensive than those
with the second binding site in the lower stem minor groove,
a first round of structure calculations focused on the inter-
molecular recognition in the upper stem binding site only.
The exact procedure used to assign the intermolecular
NOEs to each of the four degenerate sugar and linker units
of 1 is described in Supplementary Data.
A total of 150 structures were subjected to rMD. The pro-
tocol is described in detail in Supplementary Data. The
50 structures with lowest energy were subjected to a final
refinement with the incorporation of the fiRDCs to validate
the shape of the complex. In this final refinement protocol,
the attractive Lennard-Jones potential term was switched
on. The force constant for the dipolar coupling energy term
was 1.5 kcal mol1 Hz2. An accurate estimate of the mag-
nitude Dzz and rhombicity R of the alignment tensor cannot
be obtained from the powder pattern if only C–H dipolar
couplings for the base and C10-H10 ribose vectors are avail-
able. Hence we performed a grid search where we evaluated
the dipolar coupling energy term as a function of the align-
ment tensor. A systematic grid search for the optimal values
of Dzz and R was performed by sampling values of Dzz
between 5 and 10 in 1 Hz steps and values of R between
0.1 and 0.65 in 0.05 steps. Examination of the dipolar coup-
ling energy profiles revealed a minimum for Dzz ¼ 7 Hz and
R ¼ 0.55. Thus, this tensor was employed in the refinement
(29). The correlation coefficients of the experimentally
determined fiRDCs versus the calculated fiRDCs and the
Q factors of the final structures were calculated using Dipo-
Coup (30). The final structures were viewed and analyzed
using MolMol (31).
The contacts of the aminoglycoside analog 1 with the
lower stem minor groove are defined by the intermolecular
NOEs of 1 with G43-H10 and G44-H40. Owing to steric reas-
ons, these NOEs were assigned to the same sugar and linker
units of 1.
Both the RDCs and the relaxation data indicate that the
TAR/1 complex dimerizes. The procedure used for the defini-
tion of the dimer geometry and stoichiometry is explained in
Results and in Supplementary Data. Briefly, the experimental
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data are exclusively compatible with dimerization through
one molecule of 1 bridging the lower stems of two molecules
of TAR. Therefore, an additional molecule of 1 was docked
to the minor groove of two TAR/1 molecules, predisposed by
rigid body dynamics in the correct orientation to satisfy the
dimer geometry defined by the dipolar coupling data. The
docking was performed by MD simulation in explicit water
solvent and was guided by the NOEs of 1 to G43-H10 and
G44-H40.
RNase footprinting
50-32P labeled HIV-2 TAR-RNA (Scheme 1) was digested
with either RNase T1 (G-selective) or RNase A (selective
for U and C) in the presence of the aminoglycoside analogue
1 at 4C. The concentration of RNA was 10 mM, while the
concentration of compound 1 varied from 0.1mM to
10 mM. All experiments were performed in autoclaved
Eppendorf reaction vessels. Extreme precaution was taken
to avoid RNase contamination. After the reaction, the mixture
was loaded onto a 20% denaturing polyacrylamide gel for
analysis.
PACE experiment
The stoichiometry of the binding of the TAR-RNA to 1 was
verified using the PACE technique (32). A series of lanes
containing different concentrations of the aminoglycoside
(0, 1, 2, 5, 7, 10, 20, 70, 100, 200 and 500 mM) were poured
with the gel rotated by 90, as described by Cilley and
Williamson (32). The total concentration of 50-32P labeled
RNA was 10 mM.
RESULTS
Identification of the binding sites by NMR
The C10/H10, C5/H5, C6/H6 and C8/H8 RNA resonances
were monitored upon titration of the ligand in concentration
ratios varying from 1:1 to 1:100. Significant chemical shift
changes were observed up to a 10-fold excess of the ligand
(3 mM) over the RNA (0.3 mM), indicating that the equilib-
rium dissociation constant Kd is in the micromolar range or
higher. The chemical shift mapping identifies A22, U23 and
the loop nucleotides G32, G34 and A35 as the sites being
most affected by the binding of the aminoglycoside analog
1 (Figure 1). In agreement with this observation, binding of
ligand 1 protects both loop sites G32–G34 and C30 from
digestion with RNase T1 and with RNAse A, respectively
(Figure 2). These data suggest a large and unprecedented
change in the loop conformation upon binding of a positively
charged molecule to the TAR-RNA, which motivated the
choice of studying the TAR/1 complex.
The intermolecular NOESY spectrum reveals intimate con-
tacts of ligand 1 with A22, U23, U25 and A35. The atypical
C8/H8 chemical shifts of A35 in the free TAR-RNA implies
that the adenosine base is partially projected out of the loop,
thus occupying an optimal position for interacting with a lig-
and bound to the bulge on the side of the upper stem major
groove. Large chemical shifts changes are observed upon
titration of ligand 1 for the C2/H2 and C10/H10 resonances
of A35. In particular, the linewidth of the A35–C2 decreases
from 80 to 48 Hz at 900 MHz, which suggests that in free
TAR this nucleotide assumes different conformations inter-
changing on a ms to ms time scale, while in the complex
the base occupies a well-defined position. Notable is the
chemical shift change experienced by the base of G34,
which varies the most upon formation of the complex without
showing any direct contact to the ligand. This is indicative of
a profound change in the electronic environment of G34 and,
possibly, of the overall conformation of the loop, triggered by
the interaction of A35 with 1. The chemical shift change of
G34-C8/H8 is accompanied by a considerable decrease in
the transverse relaxation time T2 of G34-C8, indicating that
G34, which is disordered in the free TAR and in the TAR/
argininamide complex (33,34), undergoes a slow (ms–ms
time scale) conformational transition between two states in
complex with 1. Considerable chemical shifts changes are
observed also for the riboses of U31, G32 and G33. Clearly,
binding of the aminoglycoside analog to A35 triggers a pro-
found conformational change in the hexanucleotide loop,
which moves from a completely disordered state to a partially
ordered one.
In the bulge, the largest chemical shift changes are
observed for A22 and U23. U23 stacks on A22 in the free
TAR-RNA (33), while in this complex it is involved in
several contacts with the aminoglycoside analogue 1. The
A22–U40 base pair, which is stably formed at low tempera-
ture in the HIV-2 TAR-RNA, is disrupted in the complex, as
confirmed by the failure to observe the U40 imino resonance
even at 4C. However, several NOEs indicate that both A22
and U40 remain positioned between G21/G26 and C39/C41,
respectively.
A35 is the only loop residue that directly contacts the
ligand, suggesting that the interaction of 1 with the loop
must be part of a more complex network of interactions
holding the complex together. Cooperative binding of 1 to
both the loop and the bulge of the TAR-RNA is supported
by the chemical shift data, which indicate a Kd of comparable
size for both the bulge and the loop sites. Moreover, while 1
Figure 2. RNase footprinting. RNase protection assays of the TAR/1 complex
were carried out with 10 mM 50-32P-labeled HIV-2 TAR-RNA at 4C.
The digestion experiments were analyzed by gel electrophoresis. (A)
Digestion with RNase A (selective for C and U). Lane 1, control without
RNase; lane 2, compound 1 (10 mM); lane 3, compound 1 (5 mM); lane 4,
compound 1 (500 mM); lane 5, compound 1 (1.2 mM); lane 6, compound 1
(0.12 mM). (B) Digestion with RNase T1 (G selective). Lane 1, control
without RNase; lane 2, compound 1 (10 mM); lane 3, compound 1 (5 mM);
lane 4, compound 1 (500 mM); lane 5, compound 1 (1.2 mM); lane 6,
compound 1 (0.12 mM).
3602 Nucleic Acids Research, 2006, Vol. 34, No. 12
Downloaded from https://academic.oup.com/nar/article-abstract/34/12/3599/2375664/TAR-RNA-recognition-by-a-novel-cyclic
by fbb literatur- und sprachwissenschaften user
on 09 October 2017
inhibits the binding of Tat-derived peptides to the TAR-RNA,
linear analogues or smaller cyclic analogues of 1 do not show
any biological activity (35), underlining the importance of a
cyclic constrained structure of appropriate size for the
cooperative binding to the bulge and loop regions of the
RNA. Therefore, it is safe to conclude that one molecule of
ligand 1 binds simultaneously to the loop and the bulge of
the RNA.
A medium-sized chemical shift change of G43–C10 upon
titration of 1, together with NOEs between the aminoglycos-
ide analogue 1 and both G43-H10 and G44-H40, reveal an
additional binding site of 1 in the minor groove of the
RNA lower stem. This finding is not surprising, as structural
studies of the TAR/neomycin B complex (15) had identified
the lower stem minor groove as a binding site for positively
charged aminoglycosides.
Compound 1 can be produced with 15N and 13C labeling at
reasonable cost. In the course of this study we produced a
15N-labeled batch of compound 1 (25) with the aim of verify-
ing the existence of H-bonds between the amino groups of
the aminoglycoside analogue and the RNA phosphates by
detection of H-bond mediated 15N-31P scalar couplings.
Unfortunately, no such coupling could be observed for the
degenerate amino group.
Structure calculations including NOEs and dihedral angle
restraints were first conducted on a monomeric unit contain-
ing one TAR molecule and one ligand molecule binding to
the upper stem (Supplementary Data). The final ensemble
of 50 structures defines the binding site in the upper stem
major groove, where the most profound contacts between
the RNA and ligand 1 are situated.
Analysis of the dipolar couplings and dimerization
A few dipolar couplings of the base C–H atom pairs meas-
ured at 800 MHz assume values between 5 and 6 Hz.
These figures exceed by far those expected for the TAR-
RNA aligned in the magnetic field due to the magnetic sus-
ceptibility anisotropy of the bases (36). The largest dipolar
coupling tensor is expected for coaxial stacking of the
upper and lower stems and would correspond to a Dzz of
8 Hz and a rhombicity R between 0 and 0.1 in an 800 MHz
field. For such tensor, the largest base C–H dipolar coupling
should not exceed 4 Hz. The high values found for the
TAR/1 complex suggest that the RNA dimerizes in the pres-
ence of the ligand (37). The experimental dipolar couplings
of the two stems can be best fitted to the ensemble of 50 struc-
tures, derived from NOE and dihedral angle restraints, by
assuming a Dzz of 7 Hz and an R of 0.55. The interstem
angle after refinement with the RDCs is 60. The experi-
mentally determined dipolar coupling tensor fits well that pre-
dicted for a dimeric TAR-RNA where the upper and lower
stems of each unit form an angle of 60 and the two RNA
molecules are associated with two of their stems approxim-
ately parallel to each other and the other two stems pointing
in opposite directions (36).
The 3D 13C-edited/12C-filtered HSQC-NOESY spectrum in
D2O and the 3D
13C-edited/12C/14N-filtered HSQC-NOESY
in H2O recorded on a sample containing 150 mM 13C/15N
labelled RNA, 150 mM unlabeled RNA and 3 mM ligand
showed no intermolecular NOEs between two TAR-RNA
molecules. This finding indicates that no direct contact
between the two RNA molecules takes place in the dimer
and hence the dimerization must be mediated by one or
more aminoglycoside molecules. The presence of only one
set of resonances for the RNA further indicates that the com-
plex is symmetric.
The dipolar couplings define the relative orientation of the
two RNA units. However, it remains to be defined if the two
RNA molecules associate through the aminoglycoside
molecule bound to the upper stem major groove site or to
the lower stem minor groove site. Structure calculations
with NOE and dihedral restraints were conducted for both
cases: association through the molecule of 1 bound to the
upper stem site resulted in large NOE violations and high
energy due to severe distortion of the aminoglycoside. There-
fore, only dimerization through one molecule of 1 bound to
the lower stem minor groove is compatible with the NOE
data. With these constraints, a molecule of the aminoglycos-
ide analogue 1 was docked into the minor groove of the lower
stem of two TAR-RNA molecules, which were predisposed
in the correct orientation to reproduce the experimentally
derived dipolar coupling tensor.
PACE gel electrophoresis (32) was used to verify the stoi-
chiometry of the complex. As shown in Figure 3, the PACE
data could be poorly fitted assuming monomeric RNA
(i, ii, iv) or formation of a dimer with one or two molecules
of 1 (iii, v). Instead, a good fit of the retardation distances was
obtained assuming a dimerization step including two RNA
molecules and one molecule of 1, followed by subsequent
recruitment of two additional molecules of the aminoglycos-
ide (red curve, case vi), which supports the dimer geometry
inferred from the NMR data.
Interestingly, the longitudinal relaxation rates R1 of the
base carbons of the TAR-RNA decreased in complex with
1 by 40%. This decrease cannot be explained by invoking
internal dynamics, as it affects also the carbons of the stem
bases, whose structure remains unchanged upon binding
of 1. Instead, the smaller relaxation rates may indicate a
change in the overall correlation time of the TAR-RNA,
which also supports the dimerization model.
The upper stem-binding site
The structure calculation employing NOEs and dihedral angle
restraints, conducted on a monomeric unit containing one
TAR and one ligand molecule binding to the upper stem, res-
ulted in a well-defined structure in both stems but in a poor
definition of the relative orientation of the two stems [root
mean square deviation (r.m.s.d.) for the lower stem, 0.5 s;
r.m.s.d. for the upper stem, 0.8 s]. The structure refinement
with the C–H fiRDCs positioned the two stems at a relative
angle of 60.
The 14 lowest-energy structures of the monomeric unit are
shown in Figure 4. The RNA is well defined with a total
heavy atom r.m.s.d. (excluding the loop residues) of
0.92 s. The A-form helix structure of the lower (nt 16–21,
41–46) and upper (nt 26–29, 36–39) stems is conserved.
The upper stem helix is, however, slightly distorted, with
the a and g angles varying from the typical A-form gauche 
and gauche + conformations to the trans conformation for
residues A27–C29 and C39.
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The aminoglycoside analogue 1 binds to the bulge and the
loop residues on the major groove side of the upper stem
(Figures 4 and 5). Owing to the 4-fold symmetry of its reson-
ances and the fast kinetics of complex dissociation, the struc-
ture of 1 in the complex cannot be determined. However, the
salient features of the interaction between the aminoglycoside
analogue 1 and the TAR-RNA are well defined and the
r.m.s.d. of the whole complex excluding the loop residues
30–34 is 1.2 s.
The backbone of the 22–25 stretch opens up to allow 1 to
reach the major groove of the RNA upper stem (Figure 4).
The last base pair of the lower stem is disrupted: U40 stacks
below C39; A22 stacks below G26 but tilts away from
U40 to widen the major groove of the upper stem and
make place for the ligand. Thus, in the TAR/1 complex,
A22 and U40 belong to the upper stem, while in free TAR
they stack on the top of the lower stem G21–C41 base pair.
In agreement with the disruption of the A-form helix structure
between G21 and A22, the digestion of the TAR-RNA at
the G21 site by RNase T1 increases upon titration of 1
(Figure 2B). The planarity of the G26–C39 base pair
is slightly distorted, as indicated by the weakening of the
G26 imino resonance upon complex formation. The
p-orbitals of the U23 and U25 bases entertain hydrophobic
interaction with linker-4 and sugar-3/linker-2 of ligand 1,
respectively (Figure 5). Such hydrophobic contacts resemble
a well-known interaction motif in complexes of proteins
with oligosaccharides, where the sugars often stack below
aromatic side chains (38).
The conformation induced by ligand 1 at the bulge site of
the TAR-RNA, as well as the relative orientation of the two
stems, differ from those found in the Tat/TAR complex.
Binding of 1 does not induce either the formation of the
U23–A27–U38 base triple or the subsequent coaxial stacking
of the upper and lower stems, as it is the case for the binding
of the Tat mimetic argininamide (34). Instead, the bulge nuc-
leotides are all exposed to the solvent in the TAR/1 complex
and the axes of the two stems form an angle of 60.
The relative position of the two domains is probably a
consequence of the disruption of the A22–U40 base pair, of
the tilting of A22 to accommodate the large ligand and of
the electrostatic interactions of the ligand amino group
with the phosphate of A22.
A35 stacks on the top of the sugar-1 moiety of the ligand
and is involved in a p-cation interaction with the positively
charged amino group. This contact pulls A35 out of the
loop, causing G34 to move on the top of G36 in all structures.
In 60% of the structures G34 stacks on the top of G36, while
in the other 40% the two bases interact face-to-edge
(Figure 6). The presence of an equilibrium between two
conformations is compatible with the large linewidth of the
G34–C8 resonance, suggesting that the exchange between
Figure 4. Structure of the TAR/1 complex. (A) Superposition of the heavy
atoms of 14 structures of the TAR/1 complex based upon residues 16–21,
26–29 and 36–46. These structures had total energy <300 kcal/mol, no NOE
violations >0.5 s and no angular violations. Residues 30–35 and the bases of
U23/U25 are not shown. The lower stem is colored in blue and the upper stem
in green. A22 and U40 are highlighted in orange; the backbone of the bulge is
in magenta. The backbone and the base stacking indicate that the upper and
lower stems form an angle of 60. The aminoglycoside binding to the major
groove of the HIV-2 TAR-RNA upper stem is rendered in gray. (B) Same
ensemble as in (A) after 180 rotation around the vertical axis. The ligand is
not shown.
Figure 3. Binding stoichiometry. The function (D  DF)/(DB  DF) is plotted
versus the concentration of the aminoglycoside analogue 1 in each lane of the
PACE gel. D is the retardation distance in each lane, DF is the retardation
distance of the TAR-RNA without 1 and DB is the retardation distance of the
TAR-RNA completely bound to 1 (concentration of 1 ¼ 500 mM). The
function (D  DF)/(DB  DF) can be expressed in terms of molar fractions of
bound and free RNA, according to the procedure described by Cilley and
Williamson (32). Different binding models were assumed and the theoretical
dependence of (D  DF)/(DB  DF) on the concentration of 1 was calculated
in each case from the molar fractions assuming constant concentration of 1 in
each lane. The experimental data (red dots) were fitted to the theoretical
functions using IgorPro to derive the binding stoichiometry for the TAR/1
complex. Six different models were considered: (i) one molecule of the
TAR-RNA binds one molecule of 1 (yellow line); (ii) one molecule of
the TAR-RNA binds two molecules of 1 with the same Kd (green line);
(iii) two molecules of the RNA bind one molecule of 1 (magenta); (iv) one
molecule of the TAR-RNA binds two molecules of 1 with different Kd
(blue line); (v) one molecule of the TAR-RNA binds one molecule of 1
(TARþ 1 !kd1 C1); subsequently the TAR/1 complex dimerizes (2C1 !kd2 C2)
(close to the yellow line, not shown); (vi) two molecules of the RNA bind one
molecule of 1 (2 TARþ 1 !kd1 C1); subsequently two molecules of 1 are
recruited by the RNA dimer for a total of two RNA molecules and three
molecules of 1 (C1 þ 2 1 !kd2 C2) (red line; Kd1 	 20 mM2; Kd2 	 3 mM2).
The best fit is obtained for case (f), which supports the stoichiometry inferred
from the NMR data.
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the face-to-face and face-to-edge orientations of G34 and
G36 occurs on a ms–ms time scale.
The positively charged amino groups of the four sugars of
ligand 1 interact with various functional groups of the RNA
(Figure 5). The amino group of sugar-1 (Scheme 1) is
involved, as already mentioned, in a p-cation interaction
with A35 and in long-range electrostatic interactions with
the O2 of U25. The amino group of sugar-3 is directed
towards the major groove carbonyls of the A27–U38 and
G28–C39 base pairs in all structures but two, while the
amino group of sugar-5 is close to the phosphate backbone
of A22 and/or to the O4 of U23. Finally, no consistent contact
is found for the amino group of sugar-7. These results are in
agreement with the failure to detect H-bonding of the amino
groups of ligand 1 to the phosphate backbone of the RNA by
the JNP scalar coupling measurement, as most of the amino
groups of the ligand contact base functional groups rather
than phosphates.
Definition of the second binding site and of the dimer
geometry
Similar to neomycin (15), the aminoglycoside analogue 1
binds also to the minor groove of the lower stem of the
TAR-RNA. The chemical shift change of G43–C10 is max-
imum at a 1:1 ratio of RNA:aminoglycoside, as opposed to
the chemical shift changes in the bulge and loop region,
which increase up to a 1:10 ratio. Thus, the binding constant
of 1 to the minor groove of the TAR-RNA is higher than that
to the bulge and loop regions. This finding is confirmed by
the analysis of the PACE data (see caption of Figure 3).
The fiRDC data suggested association of two TAR/1
units with two stems of the two RNA molecules in a roughly
parallel orientation and the other two stems diverging from
each other. We identified dimer formation through the
aminoglycoside bound to the lower stem minor groove as
the only one consistent with the NOE data. The model
shown in Figure 7 is compatible with all experimental data,
including NOEs, relaxation rates, fiRDCs and PACE gel
electrophoresis. In this model, the aminoglycoside analogue
1 binds almost symmetrically to the minor groove of the
lower stems of the two TAR-RNA units. One amino group
enjoys electrostatic interactions with the negative spot created
by the phosphate groups of G21, A22 and U23, while another
amino group closely contacts the 20-hydroxyl of C45. Two
sugars and the intervening linker of 1 penetrate the minor
groove of each RNA molecule at the G43–C45 site
(Figure 7).
Figure 7. Model for the dimerization of the TAR/1 complex. The TAR-RNA
with one molecule of 1 bound to the upper stem major groove dimerizes
through an aminoglycoside molecule bound to the lower stem minor groove.
The two RNA molecules are oriented with the lower stems roughly parallel to
each other (interhelical angle  	 30) and the upper stems diverging from
each other. From the magnetic susceptibility tensor of the dimeric RNA a
dipolar coupling tensor can be calculated (Dzz, 6.8 Hz; R, 0.54), which fits
well the experimentally determined one (36). The color-coding is the same as
in Figure 5.
Figure 5. The aminoglycoside analogue 1 binds to the upper stem major
groove. (A) View of the best energy structure of the family of Figure 4.
The aminoglycoside analogue 1 (color coded by atom: dark gray, red and blue
sticks) is placed in the major groove of the upper stem of the HIV-2
TAR-RNA. A22 and U40, depicted in orange, clearly show that the hydrogen
bonds between 22 and 40 are disrupted and that A22 tilts away from the major
groove to accommodate the ligand. Besides A22 and G26, U23 (magenta),
U25 (turquoise) and A35 (pink) have direct contacts with the aminoglycoside
analogue. The positively charged amino group of the ligand sugar-1 interacts
with the p-orbital of the A35 base, the amino group of sugar-3 interacts
electrostatically with the major groove edge of G28 (dashed yellow line),
while the amino group of sugar-5 contacts the phosphate of A22 (dashed
yellow line). G34 (yellow sticks) stacks on the top of G36. The backbone of
the loop is shown as yellow lines. A similar intermolecular interaction pattern
is observed also for the other structures of the ensemble. (B) Same as in
(A) after 90 rotation around the vertical axis.
Figure 6. G34 is positioned on the top of G36. A35 interacts with the ligand
and therefore moves out of the loop. As a consequence, G34 moves on the top
of G36. The two bases interact either face-to-face (A) or face-to-edge (B).
The two conformations are likely to be in intermediate exchange (ms–ms time
scale), as inferred from the linewidth of the G34–C8 resonance.
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DISCUSSION
Binding of 1 to multiple spots of the upper stem major
groove
It is widely recognized that the intermolecular surface in
RNA/protein complexes is rather large and therefore small
molecules cannot efficiently compete with proteins for
RNA binding. Despite many efforts in the search for compet-
itive inhibitors of the Tat/TAR interaction, no drug lead has
been identified to date. The major difficulty in the develop-
ment of TAR-binders as potential therapeutic agents is their
low specificity. The problem might be alleviated by simultan-
eously targeting multiple binding sites on the TAR-RNA
(39,40). An extended effort in identifying the minimal num-
ber of interactions necessary to stabilize the Tat-bound con-
formation of the TAR-RNA resulted in the detection of two
binding sites for positively charged groups at the bulge site
and in the upper stem major groove close to A27 and
G28 (40). Synthetic ligands exploiting both binding sites
showed the highest activity and induced an RNA conforma-
tion similar to that binding to the Tat-protein (40). The amino
groups of ligand 1 contact both the bulge site and the major
groove functional groups at the G28 site (Figure 5). Although
the interaction with the bulge is suboptimal and could be
improved by introducing a guanidinium group at the C1 or
C5 of sugar-5, the amino group of sugar-3 nicely interacts
with the electron-rich spot at the G28 and U38 site
(Figure 5). Additionally, the amino group of sugar-1 interacts
with the loop residue 35. Thus, the large but flexible scaffold
of 1 allows reaching multiple binding sites on the TAR-RNA,
and therefore represents a valuable starting structure for the
design of binders that explore a large surface of the TAR
upper stem.
Cyclic scaffold of 1
The value of cyclic structures as a conformationally con-
strained backbone for TAR binders has been proven by the
design of peptidomimetics based on a cyclic, b-hairpin-like
scaffold (29), binding the TAR-RNA with a much higher
affinity than the linear analogs (41). The structure of the
BIV (bovine immunodeficiency virus) TAR-RNA bound to
one of these peptidomimetics revealed extensive interactions
with the upper stem major groove, including a conserved
hydrophobic contact of an Ile residue with the bulged-out U
of the base triple as well as electrostatic contacts of arginine
side chains with the tetraloop capping the upper stem and
with the second and third base pairs of the upper stem (29).
Intermolecular interactions of similar nature are found for
the TAR/1 complex. Analogously to the BIV TAR-RNA/
peptide complex, ligand 1 uses hydrophobic contacts to
bind to the bulge pyrimidines and electrostatic contacts to
bind to the major groove face of the upper stem base pairs
and to the loop residues. As observed for the peptides, linear
neooligoaminodeoxysaccharides show a much lower affinity
for the TAR-RNA than their cyclic analog 1 (25).
The binding of 1 induces a conformational change in the
loop of the TAR-RNA
The hexanucleotide apical loop has been found to be quite
flexible in all NMR studies (42–44), with the riboses of
C30, G33 and G34 averaging between the C20-endo and the
C30-endo conformations. Base stacking of A35 on G36 and
of G34 on G36 was found to be consistent with structural
restraints derived by NMR for a 14 and a 19 nt hairpin con-
taining the TAR hexanucleotide loop (43,44). On the basis of
such structural information, it was proposed that the apical
loop is stabilized by base stacking on both sides and possibly
by the formation of base pairs between C30 and A35+ or C30
and G34 (43). In a more recent work, biochemical analysis of
native and mutant TAR-RNAs was used together with MD
simulations to show that the apical loop of the TAR-RNA
is stabilized by a cross-loop base pair between C30 and
G34, with A35 projected out of the loop (45). This observa-
tion does not necessarily contradict the NMR studies
hypothesizing the stacking of A35 on G36. The large line-
broadening of the A35–C2 resonance of the free TAR-RNA
and the NOEs between the bases of G34, A35 and G36 are
consistent with A35 being in equilibrium between the stacked
and looped-out conformations.
This equilibrium is not present in the complex. Upon bind-
ing of 1 the NOE contacts between the base of A35 and both
G34 and G36 disappear, while several NOEs appear between
G34 and G36, indicating stacking of G34 on G36. In the
stacked conformation, the formation of the C30–G34 base
pair becomes possible; however, no evidence of this base
pair could be found in the TAR/1 complex. The ribose pucker
of G34 assumes the C30-endo conformation in the complex,
in agreement with MD simulations, where the C30-endo
pucker of the G34 ribose has been found to accompany the
stacking of G34 upon G36 (45). All in all, our data indicate
that binding of a positively charged ligand of appropriate size
to the bulge and the loop of the TAR-RNA on the major
groove side of the upper stem leads to the stabilization of
the looped-out conformation of A35 and, consequently, to
the relocation of G34 on G36.
Comparison of the TAR/1 complex with the binding of
CycT1 to the TAR loop
The formation of the Tat/TAR complex is required for the
recruitment of the P-TEFb complex and for the phosphoryla-
tion and subsequent activation of the RNA polymerase stalled
at the TAR-RNA site. The P-TEFb complex consists of the
kinase component CDK9 and the cyclin T1 subunit
(CycT1) and binds to the TAR-RNA through the CycT1 sub-
unit in a Tat-dependent manner. The interaction site of CycT1
with the TAR-RNA is localized in the apical loop. The two
atoms O6 and N7 of G34 and G32 and the presence, but
not the nature, of a nucleotide in position 35 are essential
for the interaction (4). The mechanism by which the Tat
protein favors the interaction of CycT1 with the apical loop
is not known, although it is reasonable to hypothesize that
Tat structurally pre-organizes the RNA for the binding of
CycT1.
On the basis of the structure of the complex of TAR with
the aminoglycoside analogue 1, we propose an explanation
for the dependence of the TAR/CycT1 interaction on the
Tat/TAR complex formation, which fits well the biochemical
data summarized above. We suggest that the binding of Tat to
TAR pre-organizes the hexanucleotide loop in a favorable
conformation for CycT1 binding. It is conceivable that the
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arginine-rich stretch of the Tat protein, which is responsible
for TAR binding at the bulge site, also contacts the A35 resi-
due of the hexanucleotide loop and blocks it in its looped-out
conformation, in a similar way as our aminoglycoside. The
major driving force for this contact could be the interaction
of an aromatic p orbital with a cation, similarly to that
observed for the TAR/1 complex. A generic p-cation interac-
tion provides a rationale for the insensitivity of the TAR/
CycT1 interaction to the nature of the nucleotide in position
35. A small negative effect on complex formation is observed
exclusively for the A35G mutant, where a possible cross-loop
C30–G35 base pair would destabilize the looped-out confor-
mation of the nucleotide in position 35. Supporting our hypo-
thesis, affinity cleaving experiments show that F38 of Tat is
located in the proximity of nt 34 and 35 of the TAR-RNA
(46). Furthermore, the residue K50 of the Tat-protein has
been found to cross-link with the TAR nt 34, and this inter-
action is considerably enhanced by the binding of CycT1 to
the Tat/TAR complex (4).
In the TAR/1 complex, the looped-out conformation of
A35 is accompanied by the relocation of G34 upon G36. Ana-
logously, in the Tat/TAR complex stacking of G34 upon G36
would place the O6 and N7 atoms of G34, which are essential
for the binding of CycT1, in a well-defined position in the
major groove of the TAR-RNA. The formation of a base
pair between C30 and G34 would further stabilize the position
of the G34 functional groups. In fact, such base pair has
been shown to favor the interaction of the TAR-RNA with
CycT1 without being directly involved in the complex
formation (4).
Based on the irrelevance of the nucleotide nature at
position 35, it has been hypothesized that this nucleotide
functions as a spacer with no direct contact to the proteins.
Contrarily, we suggest that A35 could be the basis of a
regulation mechanism for the formation of the Tat/TAR/
CycT1 complex based on the conformational stability of the
hexanucleotide loop.
The lower stem-binding site and dimerization
The aminoglycoside analogue 1 binds also to the minor
groove of the lower stem of the TAR-RNA, similar to neomy-
cin B (15). Furthermore the TAR/1 complex dimerizes. A
model invoking oligomerization of the TAR/1 complex
through the molecule of 1 bound to the lower stem minor
groove is compatible with all experimental data. This process
is likely to be entropy-driven and favored by the constrained
cyclic structure of 1.
Significance for drug design
The design of drug leads targeting the TAR-RNA has focused
almost exclusively on the inhibition of the Tat/TAR interac-
tion at the bulge site. However, the TAR/1 complex structure
suggests that a cyclic scaffold can be used to design ligands
that extensively bind to the entire upper stem major groove of
the TAR-RNA up to the capping loop. The interaction with
A35 might be a general feature of large ligands binding to
the major groove of the TAR-RNA, as supported by an
NOE identified in a previous study between a compound
binding to TAR in a Tat-similar manner and the A35–H8
(40). The cyclic scaffold of ligand 1 can be utilized in the
design of TAR binders, which capture A35 in the looped-
out conformation, induce the relocation of G34 on the top
of G36 and are decorated with appropriate functional groups
to compete with CycT1 for the G34 functional groups. Large
ligands, interfering with both the Tat/TAR and the Tat/TAR/
CycT1 complex formation, could represent an improved class
of drug leads both in terms of efficiency and specificity.
CONCLUSIONS
We have presented the 3D structure of the TAR-RNA in
complex with a novel macrocyclic aminoglycoside analogue.
One of the two ligand binding sites spans from the bulge to
the loop of the TAR-RNA on the side of the upper stem
major groove, thus obstructing a large part of it. In particular,
the aminoglycoside analogue 1 interacts with the residue A35
of the RNA capping loop, thereby inducing partial structuring
of the loop. We suggest that this conformational change
observed in the loop of TAR upon binding of 1 resembles
the restructuring of the loop required for CycT1 binding
and that this restructuring is induced by Tat. On the basis
of the structural information obtained in this study, we
believe that the aminoglycoside analogue 1 holds promises
to be used as a scaffold for the design of a new generation
of TAR binders that can inhibit both the Tat/TAR and Tat/
TAR/CycT1 complex formation.
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